The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.

Editor, – Thank you for including the notes on ancestim (Stemgen) in the New drugs section (Aust Prescr 2000;23:137).

We wish to point out that the approved product information states that ancestim is indicated for use in combination with filgrastim only. There have been no clinical studies of the use of ancestim with a granulocyte colony stimulating factor other than filgrastim.

Jane Campbell
Senior Regulatory Affairs Specialist
Amgen Australia
Hawthorn, Vic.